0000899243-20-018653.txt : 20200707
0000899243-20-018653.hdr.sgml : 20200707
20200707185730
ACCESSION NUMBER: 0000899243-20-018653
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200702
FILED AS OF DATE: 20200707
DATE AS OF CHANGE: 20200707
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vifor (International) Ltd
CENTRAL INDEX KEY: 0001675217
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 201016922
BUSINESS ADDRESS:
STREET 1: RECHENSTRASSE 37
CITY: ST. GALLEN
STATE: V8
ZIP: 9000
BUSINESS PHONE: 41 58 851 80 00
MAIL ADDRESS:
STREET 1: RECHENSTRASSE 37
CITY: ST. GALLEN
STATE: V8
ZIP: 9000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vifor Pharma Ltd.
CENTRAL INDEX KEY: 0001416422
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 201016923
BUSINESS ADDRESS:
STREET 1: UNTERMATTWEG 8
CITY: BERNE
STATE: V8
ZIP: CH-3027
BUSINESS PHONE: 41 58 852 81 11
MAIL ADDRESS:
STREET 1: UNTERMATTWEG 8
CITY: BERNE
STATE: V8
ZIP: CH-3027
FORMER NAME:
FORMER CONFORMED NAME: Galenica AG
DATE OF NAME CHANGE: 20071026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vifor Fresenius Medical Care Renal Pharma Ltd.
CENTRAL INDEX KEY: 0001757924
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 201016924
BUSINESS ADDRESS:
STREET 1: RECHENSTRASSE 37
STREET 2: CH-9014
CITY: ST. GALLEN
STATE: V8
ZIP: 9014
BUSINESS PHONE: 0041588518051
MAIL ADDRESS:
STREET 1: RECHENSTRASSE 37
STREET 2: CH-9014
CITY: ST. GALLEN
STATE: V8
ZIP: 9014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-02
0
0001340652
ChemoCentryx, Inc.
CCXI
0001675217
Vifor (International) Ltd
RECHENSTRASSE 37
CH-9014 ST. GALLEN
V8
SWITZERLAND
0
0
1
0
0001416422
Vifor Pharma Ltd.
RECHENSTRASSE 37
CH-9014 ST. GALLEN
V8
SWITZERLAND
0
0
1
0
0001757924
Vifor Fresenius Medical Care Renal Pharma Ltd.
RECHENSTRASSE 37
CH-9014 ST. GALLEN
V8
SWITZERLAND
0
0
1
0
Common Stock, par value $0.001 per share
2020-07-02
4
S
0
15376
56.4739
D
10661449
I
See Footnotes
Common Stock, par value $0.001 per share
2020-07-02
4
S
0
36417
57.3816
D
10625032
I
See Footnotes
Common Stock, par value $0.001 per share
2020-07-02
4
S
0
35988
57.9756
D
10589044
I
See Footnotes
In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 7,255,711 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.86 to $56.85, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6) and (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.88 to $57.87, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.21, inclusive.
VIFOR (INTERNATIONAL) LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer
2020-07-07
VIFOR PHARMA LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer
2020-07-07
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer
2020-07-07